Accord BioPharma launches Imuldosa (Biosimilar, Stelara) PFS at the lowest WAC

Shots: Accord BioPharma, a division of Intas Pharmaceuticals, has launched Imuldosa (ustekinumab-srlf), a biosimilar to Stelara The launch includes a $0 co-pay program for eligible pts with plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis Through an exclusive deal with Bio-Thera Solutions, Accord plans to introduce BAT2506, a biosimilar to Simponi, to the U.S.…

ByDipanshu DixitAugust 18, 2025

NEWS

CivicaScript is set to distribute Ustekinumab-aauz (Biosimilar, Stelara) for Chronic Inflammatory Conditions

Shots: CivicaScript announced plans to distribute the biosimilar ustekinumab-aauz for CICs incl. plaque PsO, PsA, Crohn’s disease, and ulcerative colitis, with its launch anticipated on Jan 01, 2026 Ustekinumab-aauz targets IL-12 & 23, helping regulate immune and inflammatory responses. Produced by Fresenius Kabi, it will be exclusively distributed by CivicaScript in the US and is interchangeable with…

ByDipanshu DixitAugust 5, 2025

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2024

Shots:The third quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Eli Lilly's acquisition of Morphic Holdings for ~$3.2BThis quarter also showcased multiple clinical trial results including Roche's P-I Study Data of CT-996 to treat ObesityOur…

BySaurabh ChaubeyOctober 1, 2024

TOP 20

Top 20 Oncology Companies Based on 2021 Oncology Segment Total Revenue

Shots:Oncology focuses on the study, diagnosis, prevention, and treatment of cancer based on the treatment option and it’s divided into 3 major areas including medical oncology, radiation oncology, and surgical oncologyThe advancements in cell and gene therapies have provided pharmaceutical companies with a unique set of ground-breaking tools for the development of more…

ByPrince GiriSeptember 8, 2022

TOP 20

Top 20 Immunology Companies Based on 2018 Immunology Segment Revenue

The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology- Hematology and multiple diseases but due to a drastic increase in the immune disorders- Immunology segment has been widely spared across the globe. In the top 20…

ByPrince GiriAugust 9, 2019

Accord BioPharma launches Imuldosa (Biosimilar, Stelara) PFS at the lowest WAC

CivicaScript is set to distribute Ustekinumab-aauz (Biosimilar, Stelara) for Chronic Inflammatory Conditions

PharmaShots’ Key Highlights of Third Quarter 2024

Top 20 Oncology Companies Based on 2021 Oncology Segment Total Revenue

Top 20 Immunology Companies Based on 2018 Immunology Segment Revenue

Contact US

OUR INFORMATION

FOLLOW US